Actuate Therapeutics is a clinical stage biopharmaceutical company that engaged in the developing therapies for the treatment of cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). Co. is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3ß, thereby causing the death of the cancer cells and the regulation of anti-tumor immunity. Co. operates as a semi-virtual biopharmaceutical company with expertise in all aspects of preclinical and clinical development. The ACTU average annual return since 2024 is shown above.
The Average Annual Return on the ACTU average annual return since 2024 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ACTU average annual return since 2024 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ACTU average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|